Eunsung Global (CEO Lee Ki-se), a medical aesthetics device specialist, has received approval from the U.S. Food and Drug Administration (FDA) for its high-frequency device, the Duet V. This certification represents international recognition of its technological prowess and safety, and serves as a significant step forward in strengthening its competitiveness in the global medical device market.
The Duet V delivers 4MHz radiofrequency (RF) energy to the skin, focusing heat on the subdermal layer to promote collagen remodeling and enhance skin elasticity. Equipped with a dual thermal and fractional RF system, it can be utilized in a variety of ways, including Shot and Rubbing modes, depending on the treatment goal.
The Duet V consists of three thermal tips and two fractional tips, allowing for customized treatments based on skin condition and treatment objectives. Equipped with temperature and contact sensors, it enhances stability. Its overlapping treatment effectively generates deep heat while minimizing pain, eliminating the need for direct cooling.
A representative from Eunsung Global stated, "Duet V's FDA certification is the culmination of Eunsung Global's commitment to technological innovation and quality. Building on this certification, we plan to further strengthen our position in the global market." They added, "We will continue to dedicate ourselves to developing high-quality medical devices and contribute to the advancement of the medical aesthetics industry."
- See more related articles
You must be logged in to post a comment.